(2) the so-called Estimated Shape Representation (ESR) introduced here for rapid comparison of molecules based on their 3D shapes and spatial distribution of pharmacophoric features. These methods suggest multiple progeny drugs for several parent compounds, including cases in which one progeny is predicted (i) by both similarity methods for the same parent; or (ii) by one or both methods for multiple parents. While many progenies share the same primary indication as the parent (e.g., an antiviral progeny similar to an antiviral parent), many have different and perhaps less obvious indications (e.g., immunosuppressant progeny similar to an antiviral parent). We hope that at least some of these suggestions will prove useful and will merit additional in silico analyses (e.g., docking against COVID-specific targets ), in vitro screens, and careful scrutiny by clinicians.